




RealRate

PHARMACEUTICAL 2022

Biomarin Pharmaceutical INC
Rank 175 of 471

B:OMARIN®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 329%, being 53% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	2,274,385
Cost of Goods Sold	470,515
Intangible Assets	584,851
Liabilities, Current	539,822
Liabilities, Non-Current	98,519
Other Assets	2,108,628
Other Compr. Net Income	30,571
Other Expenses	74,000
Other Liabilities	1,094,244
Other Net Income	22,328
Other Revenues	1,846,275
Property and Equipment	1,035,461
Research and Development	628,793
Selling, General and Administrative Expense	759,375

Output Variable	Value in 1000 USD
Assets	6,003,325
Liabilities	1,732,585
Expenses	1,932,683
Revenues	1,846,275
Stockholders Equity	4,270,740
Net Income	-64,080
Comprehensive Net Income	-48,794
BaseVar	5,783,884
ECR before LimitedLiability	239%
Economic Capital Ratio	329%